Synairgen Future Growth

Future criteria checks 0/6

Synairgen is forecast to grow earnings at 40.6% per annum. EPS is expected to grow by 40.6% per annum.

Key information

40.6%

Earnings growth rate

40.6%

EPS growth rate

Biotechs earnings growth30.4%
Revenue growth raten/a
Future return on equity-67.5%
Analyst coverage

Low

Last updated06 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:OMY - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2023N/A-10-4-4N/A
3/31/2023N/A-14-9-9N/A
12/31/2022N/A-18-14-14N/A
9/30/2022N/A-23-21-21N/A
6/30/2022N/A-28-28-28N/A
3/31/2022N/A-38-35-35N/A
12/31/2021N/A-49-41-41N/A
9/30/2021N/A-46-44-44N/A
6/30/2021N/A-43-48-48N/A
3/31/2021N/A-28-36-36N/A
12/31/2020N/A-14-24-24N/A
9/30/2020N/A-10-15-15N/A
6/30/2020N/A-6-6-6N/A
3/31/2020N/A-5-4-4N/A
12/31/2019N/A-4-3-3N/A
9/30/20190-4-4-4N/A
6/30/20190-4-4-4N/A
3/31/20190-3-4-4N/A
12/31/20180-3-4-4N/A
9/30/20183-1-1-1N/A
6/30/20185222N/A
3/31/20185222N/A
12/31/20175222N/A
9/30/201730-1-1N/A
6/30/20170-3-3-3N/A
3/31/20170-3N/A-3N/A
12/31/2016N/A-3N/A-3N/A
9/30/2016N/A-3N/A-3N/A
6/30/2016N/A-3N/A-2N/A
3/31/20160-2N/A-2N/A
12/31/20150-2N/A-2N/A
9/30/20150-2N/A-2N/A
6/30/20150-2N/A-2N/A
3/31/201520N/A0N/A
12/31/201441N/A2N/A
9/30/201441N/A2N/A
6/30/201441N/A3N/A
3/31/20142-1N/A0N/A
12/31/2013N/A-2N/A-2N/A
9/30/2013N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: OMY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OMY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OMY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if OMY's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if OMY's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OMY is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.